2 not yet recruiting, 2 recruiting, 1 active not recruiting. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Not yet recruiting 2, Recruiting 2, Active not recruiting 1 |
Follow NW-301V: new trials by email Literature Review of NW-301V trials Research Report on NW-301V
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation Fludarabine, Cyclophosphamide, NW-301V - Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Not yet recruiting | Neowise Biotechnology | 66 | 2026-10-01 | 2026-10-15 |
| NW-301 TCR-T in Patients With Advanced Solid Tumor NW-301V, Drug: NW-301D - Tumor, Solid | Phase 1 | Not yet recruiting | Peking University | 44 | 2025-05-10 | 2025-05-04 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Recruiting | Tao Zhang | 9 | 2024-06-19 | 2025-07-31 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Recruiting | Ting Deng | 9 | 2024-04-08 | 2025-11-25 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Active not recruiting | TingBo Liang | 18 | 2024-02-01 | 2026-10-15 |
Neoplasms (4) · Adenocarcinoma of Lung (1) · Colorectal Neoplasms (1) · Pancreatic Neoplasms (1)
Neowise Biotechnology (1) · Peking University (1) · Tao Zhang (1) · Ting Deng (1) · TingBo Liang (1)
China (5)